145results about How to "Improve enzymatic activity" patented technology

This invention relates to metabolically engineered microorganism strains, such as bacterial strains, in which there is an increased utilization of malonyl-CoA for production of a chemical product, which includes 3-hydroxypropionic acid.

Method and apparatus for processing paraffin embedded samples, e.g., to disassociate paraffin from tissue components and/or other biomolecules from the paraffin. The sample may be exposed to focused acoustic energy while held in a vessel containing a non-solvent, aqueous solution. Disassociated paraffin may be emulsified into the liquid or otherwise separated from the sample.

The present invention provides, among other things, compositions and methods for CNS delivery of lysosomal enzymes for effective treatment of lysosomal storage diseases. In some embodiments, the present invention includes a stable formulation for direct CNS intrathecal administration comprising an iduronate-2-sulfatase (I2S) protein, salt, and a polysorbate surfactant for the treatment of Hunters Syndrome.

The present invention provides, among other things, compositions and methods for CNS delivery of lysosomal enzymes for effective treatment of lysosomal storage diseases. In some embodiments, the present invention includes a stable formulation for direct CNS intrathecal administration comprising a heparan N-sulfatase (HNS) protein, salt, and a polysorbate surfactant for the treatment of Sanfilippo Syndrome Type A.

The invention discloses a Trichoderma viride F4 strain, and applications thereof. The Trichoderma viride F4 strain is stored at China General Microbiological Culture Collection Center on 10th November 2008, and preservation number is CGMCC No.2736. When the bacterial strain is used for producing cellulase taking pretreated lignocellulose as a carbon source and an inducer, the bacterial strain is capable of tolerating a plurality of inhibitors brought by pretreated lignocellulose, and producing enzyme with high efficiency; the secreted cellulase is comprehensive in composition, enzyme activity is high, and enzymolysis adaptability on pretreated lignocellulose substrate is high.

Mono-pegylated arginase conjugate and method producing thereof. The mono-pegylated arginase is homogeneous in molecular weight and shows therapeutic effect for treating cancers and viral infections. The method of producing such arginase conjugate has a main step of genetically modifying the gene encoding an arginase so that the PEG moiety can attach to the enzyme at a predetermined, specific intended site. This is achieved by removing the PEG attaching amino acid residues at undesirable sites while keeping (or adding, if necessary) the one at the desirable site of the enzyme. Two exemplary mono-pegylated arginase conjugates so produced are human arginase I (HAI) where a polyethylene glycol (PEG) moiety is site-specific covalently bonded to Cys⁴⁵ of the enzyme and Bacillus caldovelox arginase (BCA) where a polyethylene glycol (PEG) moiety is site-specific covalently bonded to Cys¹⁶¹ of the enzyme.

The present invention relates to novel halohydrin dehalogenase polypeptides and the polynucleotides that encode them. These polypeptides are useful in the production of 4-substituted-3-butyric acid derivatives and vicinal cyano, hydroxyl substituted carboxylic acid esters. The invention also provides related vectors, host cells and methods.

A microorganism is provided which has an ability to produce an L-amino acid such as L-lysine, L-tryptophan, L-phenylalanine, L-valine, L-leucine, L-isoleucine and L-serine, and has been modified to increase the activity of pyruvate synthase or pyruvate:NADP⁺ oxidoreductase. This microorganism is cultured in a medium containing ethanol or an aliphatic acid as the carbon source to produce and accumulate the L-amino acid in the medium or cells, and the L-amino acid is collected from the medium or the cells.

The invention provides compounds and compositions useful for the modulation of certain enzymes. The compounds and compositions can induce of cell death, particularly cancer cell death. The invention also provides methods for the synthesis and use of the compounds and compositions, including the use of compounds and compositions in therapy for the treatment of cancer and selective induction of apoptosis in cells.

The present invention provides, among other things, compositions and methods for CNS delivery of lysosomal enzymes for effective treatment of lysosomal storage diseases. In some embodiments, the present invention includes a stable formulation for direct CNS intrathecal administration comprising an iduronate-2-sulfatase (I2S) protein, salt, and a polysorbate surfactant for the treatment of Hunters Syndrome.

The invention provides a method of making mangel immune polysaccharides and yeasts extract, belonging to the technique field of preparing biological products, such as polysaccharides, by yeasts. Said method includes the following steps: brewers' yeast residue bitter-removing, foreign substance-removing, brewers' yeast autolysis, brewers' yeast complex enzymolysis and deactivation, segregation of polysaccharides and protein hydrolysate liquid, blink spray drying of mangel immune polysaccharides and yeasts extract, etc; it is characterized on: high yield, good quality, low cost, and could achieve the aim of preparing mangel immune polysaccharides and yeasts extract at the same time from identical yeast material, enhance the availability ratio of yeasts, avoid pollution to the environment in traditional method as a result of simply preparing one certain product and discharging other assistant liquid.

The present invention provides, among other things, compositions and methods for CNS delivery of lysosomal enzymes for effective treatment of lysosomal storage diseases. In some embodiments, the present invention includes a stable formulation for direct CNS intrathecal administration comprising an arylsulfatase A (ASA) protein, salt, and a polysorbate surfactant for the treatment of Metachromatic Leukodystrophy Disease.

The present invention provides, among other things, compositions, kits and methods for subcutaneous delivery of lysosomal enzymes for effective treatment of lysosomal storage diseases. In some embodiments, the present invention provides methods for treating Hunter syndrome by subcutaneous administration of a replacement iduronate-2-sulfatase (I2S) protein. In some embodiments, the present invention provides a kit comprising an arrangement of components for subcutaneously administering iduronate-2-sulfatase (I2S) protein.

The invention discloses a method for simultaneously preparing yeast extract and beta-1,3-glucan, which belongs to the field of preparation of yeast extract and beta-1,3-glucan. The method comprises the steps of bitter removal and impurity removal of beer waste yeast, enzymolysis and inactivation of the beer waste yeast, separation and drying of the yeast extract, acid and alkali treatment, washing and drying of the beta-1,3-glucan and the like. The method has the characteristics of high raw material utilization rate, good quality, low cost, easy industrialization and the like, realizes reutilization of the beer waste yeast, and fulfills the purpose of simultaneously producing two products comprising the yeast extract and the beta-1,3-glucan.

An aqueous alcohol-containing well treatment fluid containing a polysaccharide derivative as gelling agent, optionally crosslinked, is capable of being degraded at elevated temperatures by the presence of an enzyme and an organic acid ester. The well treatment fluid has particular applicability in the treatment of low pressure gas producing wells.

The present invention provides polynucleotides encoding potassium channels as well as methods of using the potassium channels to treat and diagnose diabetes and a predisposition for diabetes.

The present invention is concerned with new micro organisms, preferably mutagenised, belonging to the genus Agrobacterium radiobacter able to convert nitriles and/or amides into their respective acids, in addition to conversion processes utilising said micro-organisms.

A composition comprising mesoporous aggregates of magnetic nanoparticles and free-radical producing enzyme (i.e., enzyme-bound mesoporous aggregates), wherein the mesoporous aggregates of magnetic nanoparticles have mesopores in which the free-radical-producing enzyme is embedded. Methods for synthesizing the enzyme-bound mesoporous aggregates are also described. Processes that use said enzyme-bound mesoporous aggregates for depolymerizing lignin, removing aromatic contaminants from water, and polymerizing monomers polymerizable by a free-radical reaction are also described.

The present disclosure provides a variant tyrosine hydroxylase that provides for increased production of L-DOPA in a host cell that expresses the tyrosine hydroxylase. The present disclosure provides nucleic acids encoding the variant tyrosine hydroxylase, and host cells genetically modified with the nucleic acids. The present disclosure provides methods of making L-DOPA in a host cell. The present disclosure provides methods of making a benzylisoquinoline alkaloid (BIA), or a BIA precursor. The present disclosure provides methods of detecting L-DOPA level in a cell. The present disclosure provides methods of identifying tyrosine hydroxylase variants that provide for increased L-DOPA production; and methods of identifying gene products that provide for increased tyrosine production.

A method of controlling a physical characteristic of polymeric nanocarrier-encapsulated protein particles includes altering or selecting a weight percentage of a hydrophobic polymer block in a total amphiphilic diblock copolymer of a primary emulsion of a double emulsion, freeze-thaw technique. The primary emulsion is formed using a freeze-thaw cycle of the amphiphilic diblock copolymer and a protein having a molecular weight of up to or equal to 300,000 Da. Selection of the hydrophobic polymer block percentage alters one or more characteristics of the resulting nanoparticles, such as shape. Thus, as one aspect, a method of producing filamentous polymeric nanocarrier-encapsulated protein (i.e., active enzyme) particles involves forming a primary emulsion using a freeze-thaw cycle of (i) an amphiphilic diblock copolymer, which has a molecular weight of about 10,000 to about 100,000 Da and comprises a conjugate of the hydrophobic polymer block and a hydrophilic polymer block, wherein the amphiphilic diblock copolymer comprises greater than 81% to about 95% by weight of the hydrophobic polymer block; and a protein having a molecular weight of up to or equal to about 300,000 Da. Various compositions comprising such filamentous-shaped nanocarrier particles, and methods of use for diagnosis and therapy are disclosed.